AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$HNGE

Budge James sold $4.9M of HNGE

Budge James (Chief Financial Officer) sold 47,720 shares of Hinge Health, Inc. (HNGE) at an average of $103.13 ($101.53–$104.34, $4.92M total) across 4 trades on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Budge James
Published Oct 13, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 9:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HNGE
Bearish
medium confidence
Mentioned
$HNGE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HNGEBearishLow
01

Why it matters

The transaction is material for Hinge Health and may influence short‑term sentiment, but the remaining insider ownership remains substantial.

02

Market read

First‑report insider sale of $4.9M by the CFO, likely to generate modest bearish pressure on HNGE.

03

What to watch

The CFO's remaining stake remains sizable; the sale may simply be portfolio rebalancing rather than a red flag.

Relevance 5/10Novelty 5/10Timing: after-hours

Background

SEC Form 4 filings provide primary‑source disclosure of insider transactions. This filing reports a CFO's sale of nearly 48k shares at an average price of $103.13.

Company-level read

Ticker impact

$HNGEBearishMedium confidence
Context

CFO Budge James sold 47,720 shares for $4.9M via a 10b5-1 plan, reducing his stake to 296,728 shares.

Expected impact

likely pressure as the market prices in the CFO's sell-off

Evidence & confidence

A $5M sale by the CFO is material for a mid‑cap health‑tech firm and is the first public disclosure of the transaction.

Market effects

Sector

Healthcare technology sector may see modest sell pressure as insiders reduce holdings.

Regional

US market participants may adjust exposure to HNGE in the near term.

Global

Limited; impact confined to the company's stock and its immediate investors.

Counterpoint

What could challenge this read

The sale could be a routine 10b5-1 execution unrelated to fundamentals, offering a buying opportunity.

Key entities

  • person
    Budge James

    Chief Financial Officer of Hinge Health, Inc.

  • company
    Hinge Health, Inc.

    US‑listed digital health company (ticker HNGE).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HNGE insider trading history →

Related articles

$HNGEHighAI 8/10

Needham raises Hinge Health stock price target on client growth

Needham raised its price target for Hinge Health (NYSE:HNGE) to $135 from $115, citing strong client growth and quarterly performance. The company reported 28% year-over-year client growth, 50% revenue increase, and 154% stock return over six months. Q3 revenue was $235 million, up 52% year-over-year, with EPS of $0.66 beating estimates. Wells Fargo also raised its target to $132, noting strong margins and revenue growth.

investing.com
$HNGEHighAI 8/10

Hinge Health (HNGE) Q3 2026 Earnings Call Transcript

Hinge Health (HNGE) reported Q3 2026 revenue of $235M, up 52% YoY, with gross margin at 88% and operating income at $77M. The company highlighted growth in its MSK, Migraine, and GI care programs, with strong early results in Migraine care. President Jim Pursley announced his departure at year-end to spend more time with family but will join the board.

finance.yahoo.com